Posts

7 days in healthcare (December 12th-18th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, The Lancet commemorates the 200th anniversary of the birth of Pasteur, the creator of the germ theory. Even today a high percentage of deaths are from infections. Promising results of an mRNA vaccine against melanoma, presented by Moderna and Merck.

As far as Global Health is concerned, it is worth highlighting the article published in Nature that says that without a strategy and global financing of vaccines, the world will be unable to successfully face new epidemics.

As for international health policy, the discouraging news of China’s abandonment of the covid-zero policy continues, when the country is not prepared and is most likely to suffer high mortality. The CDC quantifies the deaths from persistent covid in the USA. The conflict of nurses in the NHS continues, which coincides with the appearance of a report from the Institute for Fiscal Studies in the United Kingdom that attributes the problems of the NHS to underfunding of the system. New Zealand, the second country in the world to announce a ban on tobacco sales.

If we talk about national health policy (Spain), in terms of covid, the incidence continues to decrease, what has not completely decreased, or has decreased very slowly, is mortality (236 deaths in the last week). After confinement in a unit of the Regional Ministry of Health, the strike committee of primary care doctors in Madrid decided to continue the strike, extending the conflict to a demonstration, along the lines of the “white tides”.

In the field of companies, internationally, it seems that Jeff Bezos and Bill Gates are making an important bet in the field of neurotechnology with the company Synchron. As far as national news is concerned, perhaps highlighting that it seems that the hopes placed on the Spanish HIPRA vaccine are fading.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

 

 

 

7 days in healthcare (February 21-27, 2022)

/in /by

SUMMARY

From the point of view of biomedicine, Bill Gates predicts another pandemic, although he estimates that he will catch us better prepared. Also to highlight the questioning of the traditional form of clinical trials. The latter is important, since Spain has become a power in clinical trials and it is important to analyze whether it is the right bet.

In terms of global health, it should be noted that COVAX has distributed exactly half of the COVID vaccines that it had as its objective. A great inequity in the distribution of vaccines in the world and, now, also of medicines against COVID.

As for international health policy, great controversy in the United Kingdom due to the lifting of all restrictions against COVID.

In national health policy (Spain), the incidence of COVID is low, although we continue with high mortality and without antivirals. The Ministry of Health takes the expansion of the service portfolio to a public hearing. Medical uneasiness before the reform of the Abortion Law, a BIOSIM proposal to promote the use of biosimilars and controversy over the financing of orphan drugs.

With regard to companies, it should be noted that the manufacture of Ventolín and Nolotil pollutes more than the automotive industry, which indicates how far the pharmaceutical industry has to go in implementing the United Nations Sustainable Development Goals. Also that Quirónsalud has exceeded the turnover of 4,000 million and Fresenius is open to incorporating new shareholders both in Quirónsalud and Eugin.

BIOMEDICINE

GLOBAL HEALTH

INTERNATIONAL HEALTH POLICY

NATIONAL HEALTH POLICY (SPAIN)

  • COVID

o The incidence of COVID continues to drop to 613 cases per 100,000 inhabitants (https://elpais.com/sociedad/2022-02-24/ultima-hora-del-coronavirus-hoy-en-espana-y-el-mundo-en-directo.html)

o 245 deaths in the sixth wave and still without antivirals (https://www.larazon.es/sociedad/20220225/3eq7hmpczjfe3ct7ruk3tz56wi.html)

o The subvariant of the stealthy “ómicron” accelerates its expansion in Spain (https://www.larazon.es/sociedad/20220224/3zfep56h6bf7jktf4fqvbnj3yq.html)

  • Political announcements

o The Ministry of Health takes out the draft order for the expansion of the service portfolio for a public hearing. Opinions in this regard can be sent via email informacion.publica@mscbs.es until March 10 (https://www.consalud.es/politica/sanidad-saca-audiencia-publica-orden-ministerial-actualiza-cartera-comun-sns_110420_102.html)

o AIReF announces a study on MUFACE spending in its plan for 2022 (https://www.airef.es/es/noticias/la-airef-publica-su-plan-de-actuaciones-2022-con-una-apuesta-clara-por-la-sostenibilidad-y-la-evaluacion/)

  • Other issues

o The medical groups, against the reform of the abortion law, propose the obligatory nature of performing it in public hospitals (https://www.larazon.es/sociedad/20220225/onwymfclwbbyfiamuan5il533e.html)

o Biosim presents 14 proposals to stimulate the use of biosimilars (https://www.diariofarma.com/2022/02/24/biosim-plantea-14-propuestas-para-fomentar-el-uso-de-los-biosimilares )

o Great controversy over the financing of orphan drugs, while the Ministry publishes a report with improvements in financing since 2016 (https://www.diariofarma.com/2022/02/23/sanidad-publica-un-analisis-sobre-la-financiacion-acceso-y-gasto-de-los-medicamentos-huerfanos-desde-2016) others insist that more than 50% of these medicines are not publicly funded (https://www.redaccionmedica.com/secciones/industria/el-50-de-los-medicamentos-huerfanos-estan-sin-financiar-en-espana-7267)

o The strategic health reserve today has 466 million masks and 955 respirators (https://www.elindependiente.com/espana/2022/02/27/la-reserva-estrategica-de-sanidad-cuenta-hoy-con-466-millones-de-mascarillas-y-955-respiradores/)

COMPANIES, EMPLOYERS AND OTHER AGENTS IN THE SECTOR

 

7 days in healthcare (January 17-23, 2022)

/in /by

 

SUMMARY

From an international point of view, the article published in The Lancet should be highlighted, in which mortality due to antimicrobial resistance, one of the most important causes of death in the world, is analyzed at a global level. Also the demand of the British Medical Journal that the scientific community have access to all the original data on the clinical trials of vaccines, since at this time these data are only accessible to employees of pharmaceutical companies. The Economist analyzes if the mandatory nature of the vaccine works, concluding that it does. It looks like all the COVID restrictions in England are going to end soon. The European Union gives more powers to the EMA, in case of having to manage future health crises.

As for the national news, the pandemic is still unchecked, in very high numbers and with high mortality; the debate on treating the covid as influenza continues, with opposing positions, those who are against it and those who defend it; the Ministry of Health wants to advance in the recertification, in dialogue with the FACME and the Organization of Medical Orders; The situation of health insurance in 2021 is presented, which did not stop growing, until the sector as a whole reached a turnover of close to 10,000 million euros; the Madrid College of Physicians signs a controversial agreement with UNIPROMEL, in theory to “defend doctors in free practice”, but, more possibly, with the intention of reinforcing the current weakened board of directors.

As far as companies are concerned, perhaps the most outstanding news is the sale by IBM of Watson Health, the artificial intelligence solution, designed to solve diagnostic and therapeutic problems, which had had so many problems in some centers such as MD Anderson from Houston. Although it was a good and ambitious idea, it was possibly ruined by short-termism, hyperselling and not taking enough into account the complexities of medicine and medical practice.

INTERNATIONAL NEWS

  • The Lancet publishes an article on the mortality of antimicrobial resistance. 204 countries and territories are analyzed in 2019. 4.95 million deaths from antimicrobial resistance were found in 2019. Antimicrobial resistance is one of the most important causes of death in the world (The Lancet, 20 January 22)
  • The British Medical Journal, after the Tamiflu experience, asks that the original data (raw data) from the clinical trials of vaccines be accessible to all researchers, not just those from the pharmaceutical industry, as is the case now (BMJ, January 19, 22)
  • The WHO gives the green light to the wider use of the third dose against COVID (FT, January 21, 22)
  • The fourth dose of the vaccine, infective in the extension of the “ómicron” variant, according to an Israeli study (FT, January 18, 22)
  • The Economist analyzes if the compulsory nature of the vaccine works. After analyzing the cases of Canada, France, Italy and Germany, he concludes that it works (The Economist, January 22, 22)
  • The covid passport strengthens the economy and vaccination (FT, January 18, 22)
  • Bill Gates warns against a pandemic potentially worse than COVID and calls on governments to spend billions of dollars to prevent it. He also says that this effort can contribute to improving the prevention and treatment of current extended diseases: HIV, tuberculosis, malaria (FT, January 19, 22)
  • All restrictions in England may end in March, according to the British Prime Minister’s plans (The Guardian, 17 January 22)
  • The EU approves the reform that gives more powers to the EMA in the management of future health crises (The Objective, 20 January 22)
  • Italy registers an increase in vaccination, after making it mandatory for those over 50 years of age (El País, January 17, 22)

NATIONAL NEWS

  • Situation of the pandemic

o COVID, still unchecked, breaks a new record of 3,418 cases per 100,000 inhabitants (El País, January 21, 22)

o The ICUs are at the limit of their structural capacity but far from the worst moments (El País, January 17, 22)

  • Debate about dealing with the covid as if were “flu”

o Two opposing positions:

 “Gripalizing the covid or how to believe we are winners”, article by Santiago Cervera, January 15, 22)

 Antonio Zapatero is committed to self-care and not to restrictions (El Español, January 17, 22)

  • Sick leave

o Processed 21,000 sick leaves and registrations in Madrid in the first days of the new system (El País, January 20, 22)

o The doctors accuse Escrivá of violating the law with the casualties, by giving in the same act for 7 days (La Razón, January 17, 22)

  • Recertification

o The Ministry of Health commits with FACME and the WTO to promote professional recertification (Acta Sanitaria, January 21, 22)

  • Situation schools

o The avalanche of school confinements puts families on the ropes (El País, January 21, 22)

  • Health insurance

o Health insurance grows by 4.93% in 2021 and totals 9,849 million euros (Acta Sanitaria, January 18, 22)

o According to forecasts by Javier Murillo, health insurance will grow in 2022 by around 5.5-6% (presentation at ICEA)

o MJ Montero (Finance Minister): great support for the MUFACE system (MUFACE Magazine, nº 252, winter 2021)

  • Other issues

o Organ transplants overcome the slump of 2020 and grow 8% in 2021 (El País, January 21, 22)

o Argimón presents the 2021-2025 health plan (Consalud, January 20, 22)

o Health, forced by Transparency to deliver to Farmaindustria the minutes of the Pharmacy Commission of the Interterritorial Council (diariofarma, January 16, 22)

o The MIR exam will bring together candidates from 4 continents and 88 countries (redacción Médica, January 20, 22)

o The Madrid College of Physicians signs an agreement with UNIPROMEL, “to defend free practice physicians” (Official Note ICOMEM, January 21, 22)

o Health awards 81 linear accelerators, in compliance with the INVEAT plan, three lots: Ab Salud, Varian and Elekta (ConSalud, January 18, 22)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

  • IBM sells Watson Health to an investment firm. The sale was preceded by resounding failures of this artificial intelligence tool for medical diagnosis and treatment (WSJ, January 21, 22)
  • Moderna intends to launch a joint COVID-flu vaccine in two years (The Guardian, January 17, 22)
  • Djokovic has 80% of the shares in a Danish biotech firm (QuantBioRes) that intends to release a vaccine against COVID (The Guardian, January 19, 22)
  • Pfizer becomes the largest provider of the pandemic and it is estimated that it will double its income (eldiario.es, January 17, 22)
  • Pfizer, AstraZeneca and the Chinese Sinopharm and Sinovac will manufacture 70% of the COVID vaccines (CincoDías, January 20, 22)
  • Merck entrusts the manufacture of its pill against COVID to 27 manufacturers (PlantaDoce, January 20, 22)
  • More than 100 laboratories in Asia and Africa could manufacture vaccines for Pfizer and Moderna (El Independiente, January 19, 22)
  • The “telecos” take advantage of the pandemic to add clients in telemedicine (El Independiente, January 19, 22)
  • AstraZeneca, the most widely used COVID vaccine in the world that is no longer administered in Spain (El Español, January 21, 22)
  • St John of God (important hospital network in Spain, until now divided into three “provinces”) consolidates its management structure at the national level (Acta Sanitaria, January 20, 22)
  • Acciona, Sacyr and OHLA bid for a new hospital in Chile for 265 million euros (PlantaDoce, January 16, 22)
  • Dental Residency, objective by 2022 to double billing and provide coverage to 250,000 residents (PlantaDoce, January 20, 22)
  • The EMA asks HIPRA to show greater efficiency than Pfizer, if it wants to be part of the European Union’s portfolio (El Economista, January 18, 22)
  • HIPRA will carry out the last clinical trial of its vaccine at HM Hospitals (El Economista, January 17, 22).
  • Viamed is preparing an offer for one of the “Catholic” hospitals in Madrid: San Francisco and Beata María Ana (Sanifax, January 21, 22)
  • ASISA renews its Board of Directors with three members, one internal and two independent directors (Europa Press, January 20, 22)
  • Mercadona offered the Government to sell tests in its establishments at 2.90 euros. The Government preferred to keep pharmacies as the only test point of sale (Sanifax, January 20, 22)
  • Lilly publishes an overview of start ups in health in Spain (Lilly, January 22)

7 days in healthcare (January 10-16, 2022)

/in /by

 

SUMMARY

From the international point of view, several issues stand out. In the first place, the agreement of the French Assembly taken on Sunday, January 16, to prevent the access of the unvaccinated to leisure and restaurant premises; also Quebec’s initiative to introduce special taxes on the unvaccinated; the WHO’s opinion that it is too early for COVID “flu” policies, as proposed by Spain; the calculation by ISGlobal (Barcelona) that COVID has already left 17 million deaths globally; and the big push for research on neurodegenerative diseases.

As for national news, the SEMFYC (one of the Primary Care medical societies) editorial had a great impact defending the “flu” policies of COVID and, therefore, the minimization of measures, encouraging, consciously or unconsciously, the “light” negationism. This position was quickly adopted by the central government and certain authorities of the Community of Madrid. The central government even tried to lead this position at the international level. Rejection of this idea by other Primary Care societies, a large number of experts, the WHO and the EU. Meanwhile, the incidence of COVID continues to rise to figures never seen in other waves (2,923 cases per 100,000 inhabitants). The price of antigen tests is regulated, after multiple requests from various groups. It is agreed to extend the third and fourth doses. Serious problems regarding sick leave, for which solutions are articulated about the legality of which is in doubt. The purchase of COVID medicines is announced. Ayuso Plan to stimulate the birth rate in Madrid.

As far as companies and other actors are concerned, a group of scientists in Texas announce a vaccine against COVID, which, according to them, it will be cheaper, easier to make and patent-free. Pfizer announces that it will have a new vaccine against the “ómicron” variant ready in March

INTERNATIONAL NEWS

  • France: the Assembly approves by 215 votes against 58 the law that prevents the access of the unvaccinated to leisure and restaurant venues (Le Monde, Jan 16, 22)
  • Quebec’s plan on special taxes on the unvaccinated is well received in Europe. the argument is: “10% of the population cannot overload 90%”. Cold reception at the federal level in Canada and in other provinces. However, in Europe it is not receiving a bad reception: Greece and Austria already fine the unvaccinated, Italy is studying it, France extends the “covid passport” (BMJ, Jan 14, 22)
  • Fourth dose in Israel, which had already been announced for the immunosuppressed, is now being extended to health professionals and those over 60 years of age (Lancet Respir Med, Jan 11, 22)
  • The WHO considers that it is too early to treat COVID-19 as endemic, contradicting the Spanish government’s proposal, and predicts that half of Europeans can be infected (FT, Jan 11, 22)
  • COVID-19 pushed millions of Indians into poverty (The Economist, January 12,22)
  • Some experts predict a new COVID wave at the beginning of the summer (The Guardian, Jan 14, 22)
  • China’s zero COVID policy is creating problems for the manufacturing and distribution chain sectors (FT, Jan 16, 22)
  • Beijing reports the first case of the “ómicron” variant (The Guardian, Jan 15, 22)
  • COVID would have already left 17 million dead in the world (the official figures are 5.5 million), according to a study by the Barcelona Institute for Global Health, sponsored by the La Caixa Foundation (Diario Médico, Jan 15, 22)
  • The Epstein-Barr virus may play a role in the development of multiple sclerosis (NYT, Jan 13, 22)
  • The Economist looks at how healthcare is evolving into a consumer product (The Economist, Jan 15, 22)
  • Great boost to research on neurodegenerative diseases, with 260 drugs under development: Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS), Huntington’s, multiple sclerosis, multiple systemic atrophy, Parkinson’s and others (Diariofarma, Jan 14, 22)

NATIONAL NEWS

  • Incidence of COVID and evolution of the sixth wave

o As of January 13, 2022, the 14-day cumulative incidence of COVID amounts to 2,923 cases/100,000 inhabitants. It is not clear if the peak of the wave has been reached or if we are still going up. In any case, the figures are very high (Official data Ministry of Health, update to  Jan 13, 22)

o Almost half of the Spanish provinces have ICUs at very high risk (El País, Jan 12, 22)

o The debate on those hospitalized “for” COVID and “with” COVID is introduced (El Independiente, Jan 10, 22)

  • “Influenzaization of the pandemic”

o An editorial in a journal of the SEMFYC (Spanish Society of Primary and Community Care Physicians), one of the three scientific societies of Primary Care, advocates the “influenza” approach  of the COVID, avoiding counting individual cases and omitting general measures of protection (AMF-SEMFYC, Towards the end of the exceptionality, Jan 10, 22)

o The other scientific societies of Primary Care, as well as most of the experts, took a stand against the previous proposal, at least until the sixth wave was passed.

o Notwithstanding the foregoing, both the President of the Government and Minister Darias, and certain representatives of the Community of Madrid, expressed their agreement with the approach as “influenza”

o Not only that, but that approach was taken to the WHO, which showed its disagreement. Spain wants to lead this debate in the EU (El Periódico de España, Jan 12, 22)

  • Regulation of the price of antigen tests

o The government (Interministerial Commission on the Price of Medicines) limits the price of antigen tests to 2.94 euros and they will continue to be sold only in pharmacies, with entry into force on Saturday, January 15, 2022. The price is 50% more expensive than in France and Germany (El País, Jan 13, 22)

o During the free sale period, the gross margin for pharmacies was 25-50% (El Economista, Jan 13, 22)

o FEFE expresses its “deep discomfort” at having to sell the tests at a loss (diariofarma, Jan 14, 22)

  • The third and fourth doses are extended

o The Ministry of Health announces a fourth dose for patients at risk and will extend the third to those over 18 years of age (La Razón, Jan 13, 22)

  • Purchase of COVID medications

o Spain closes an agreement with Pfizer to buy 344,000 doses of its drug against COVID

o The regions were unaware of this and ask for an equitable distribution (El Español, Jan 11, 22)

  • Serious problem with sick leave

o COVID causes more than 10,000 sick leaves per day in Spain (El Independiente, Jan 11, 22)

o This situation collapses health centers

o A system is put in place so that discharge and discharge (after 7 days) take place in the same act. Madrid calls for a regulatory change, to which the Government does not seem willing (El Economista Jan 12, 22)

  • Ayuso Plan to stimulate the birth rate in Madrid

o It is intended to go from 50,000 to 70,000 births/year in the region. The plan consists of aid of 500 euros, flexible working hours, deductions and support for assisted reproduction (La Razón, Jam 10, 22)

  • Other themes

o FACME disagrees with the recertification plan of the Ministry of Health, which launched a tender to hire a consultant (Official note from FACME,  Jan 13, 22)

o Teachers facing the return to classes, doubts with the new protocol and fears (El País, Jan 10, 22)

o A court condemns the Generalitat Valenciana to compensate the toilets for not giving them the means of protection (El País, Jan 11, 22)

o Ingesa attempts an agreement on biosimilars, which does not have the agreement of BIOSIM (diariofarma, Jan 9, 22)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

  • A group of scientists in Texas announce a vaccine (CORBEVAX) that is cheaper, easier to make and patent-free (The Guardian, Jan 15, 22)
  • GSK rejects UNILEVER’s offer of 50,000 million pounds for its consumer division (FT, Jan 15, 22)
  • Medicare introduces major restrictions on the use of Biogen’s drug against Alzheimer’s (NYT, Jan 11, 22)
  • Adeslas will enter 1,655 million euros for MUFACE and ASISA 1,268 (PlantaDoce, Jan 12, 22)
  • Vivanta adjusts its network of centers, putting its beauty business up for sale (PlantaDoce, Jan 12, 22)
  • Pfizer says that it will have a new vaccine against “ómicron” ready in March (Redacción Médica, Jan 10, 22)
  • Merck acquires the US company EXELEAD for 789 million dollars (PlantaDoce, Jan 7, 22)
  • Medtronic reaches an agreement to acquire Affera (ConSalud, Jan 14, 22)
  • Eugin acquires the Delaware Institute of Reproductive Medicine (PlantaDoce, Jan 10, 22)
  • Caser Residencial acquires a new social health center in Laguna de Duero (PlantaDoce, Jan 13, 22)

7 days in healthcare (December 20-26, 2021)

/in /by

 

 

Summary

From an international point of view, possibly the most interesting is the summary of the year 2021 by The Lancet; also the studies that seem to show that the “omicron” variant is not only more contagious (which was already known), but that it produces a milder form of disease; the NEJM analyzes Amazon’s health offering; and finally, Israel’s attempts to move forward with the fourth dose.

As for national news, the most relevant thing is the great increase in the pandemic in Spain, which fundamentally translates into pressure on Primary Care and Emergencies, not so much in hospitals; the attitude of the central government in the Conference of Presidents of not imposing restrictive measures, in contrast to what is being done in other European countries; and the failures of the strategic reserve in health, which is causing a great shortage of antigen tests at this time.

With regard to companies and other agents in the sector, it is important to highlight that Europe approves the Novavax vaccine, which would already be the fifth vaccine approved in Europe. Also the authorization of the Merck pill by the FDA for high risk covid. From the point of view of corporate movements, perhaps the most relevant is the purchase of CERNER by Oracle, which may revolutionize the field of hospital informatics.

International

 

  • Farhat Yaqub summarizes for The Lancet the most notable events of 2021 in health: the COVID-19 pandemic, which had produced 3.3 million deaths globally as of December 10, 21, more than in 2020; COVID vaccination, with more than 8.4 billion doses administered through December 11; Biden instead of Trump, one of Biden’s first actions was to sign the executive order for the US to return to the WHO; the health impact of the conflict in Ethiopia; the effects of the decline in UK development aid; the COP 26 meeting in Glascow, which put climate change on the health agenda; the crisis in Afghanistan, the most serious current humanitarian crisis; abortion laws: legal in Argentina, banned in Honduras, severe restrictions in Texas; restrictions also in China; the approved malaria vaccine; severe shortage of midwives (The Lancet, Dec 18 21)
  • Three studies (England, Scotland and South Africa) show that the “omicron” variant produces milder COVID, with much less chance of being admitted to hospital (British Medical Journal, 23 Dec 21)
  • A NEJM article looks at Amazon’s healthcare offering: a combination of telemedicine and home care. Three main actions: mobile app; home assessment by a nurse; distribution of medication at home in two hours. A hybrid experience online and in person (NEJM, 23 Dec 21)
  • COVID vaccines are less effective against the “omicron” variant, says the EMA (FT, Dec 20 21)
  • Israel May Give Fourth Vaccine Dose, Despite Expert Reservations (NYT, Dec 23 21)
  • The “omicron” variant responsible for 75% of the cases in the USA (FT, Dec 21, 21)
  • The “omicron” variant has revealed a world not yet prepared for pandemics (FT, Dec 22 21)
  • US military announce SpFN, a valid vaccine against all variants of the coronavirus, including “omicron” (La Razón, Dec 22 21)
  • The “omicron” variant causes the cancellation of almost 5,000 flights around the world during the days of Christmas Eve and Christmas (CincoDías, 25 Dec 21)

National News

  • The incidence of COVID shoots up to 911 cases per 100,000 inhabitants in the last 14 days (El País, 23 Dec 21)
  • Germany declares Spain as a high-risk territory due to COVID (El País, 23 Dec 21)
  • Sánchez prioritizes the economy in the sixth wave and avoids any restrictive measure in the Conference of Presidents, apart from the mandatory nature of outdoor masks and certain possibilities of hiring professionals without recognized degrees (La Razón, Dec 24 21)
  • Feijóo, Moreno, Urkullu and Aragonés consider that the mask on the street is not enough (El Confidencial, Dec 22 21)
  • Harsh criticism from the General Council of Medical Associations in the absence of measures against COVID: “they seek formulas to avoid the burden of responsibility and fear to implement measures that contradict or further anger citizen-voters” (La Vanguardia, Dec 24 21 )
  • The ICUs of ten communities are already at “high risk” due to patient occupation (Aragon, Asturias, Balearic Islands, Cantabria, Castilla y León, Catalonia, Valencian Community, Navarra, Basque Country and La Rioja) (Vozpópuli, Dec 24 21)
  • The sixth wave will leave 9,000 dead in Spain, according to a study by the University of Washington (IHME, Covid 19 Results Briefing, Spain, December 23, 21)
  • The strategic health reserve falls short and does not alleviate the shortage of tests (El Periódico de España, Dec 25 21)
  • Spain has practiced a hundred euthanasias since the approval of the new law (The Objective, Dec 18 21)
  • Strong statements by President Díaz-Ayuso: “In some health centers, not everyone wants to work and pitch in” (El País, Dec 21, 21)
  • SEMERGEN demands that Díaz-Ayuso reconsider her statements about primary care (ConSalud, Dec 22 21)

Companies, employers and main health actors

 

  • Europe approves the Novavax vaccine. It would be the fifth COVID vaccine approved in Europe, after those of Pfizer-BioNTech, Moderna, AstraZeneca and Janssen (FT, Dec 20 21)
  • Biogen cuts the price of its Alzheimer’s drug in half, due to low sales and divisions by experts about its benefits (FT, Dec 20 21)
  • Merck’s COVID pill is FDA cleared for high-risk adults (NYT, Dec 23, 21)
  • FENIN report on the hospital technological profile, with data updated to December 2020. FENIN has been conducting this study since 2009 (FENIN, Dec 21)
  • “MiQuirónsalud”, the portal that the hospital group makes available to its patients, exceeds four million users (ConSalud, Dec 21 21)
  • Oracle buys CERNER for more than 28,000 million euros to grow in health (PlantaDoce, Dec 22 21)
  • Atrys Health acquires 100% of Simm Molecular, which is dedicated to medical diagnosis in nuclear medicine (PlantaDoce, Dec 17 21)
  • Health in code and the Portuguese Algarve Biomedical Center sign an agreement for genetic diagnosis (PlantaDoce, Dec 22 21)
  • MBA (a medical technology company very oriented to orthopedics-traumatology and based in Asturias), until now owned by Alantra, is acquired by the Swedish group Addlife for 111 million euros (Medical Writing, 23 Dec 21)
  • Viamed, owned by the Macquarie fund, acquires the Fuensanta hospital in Madrid, until now owned by the Merina family. With this, Viamed now reaches 12 hospitals in Spain (PlantaDoce, 23 Dec 21)

7 days in healthcare (November 29-December 5, 2021)

/in /by

 

SUMMARY

From the international point of view, it is worth highlighting the beginning of the work of the WHO for the approval of a Treaty on pandemics. It seems that the alarm about the new “‘ ómicron “variant is lowered, after the WHO announcement that there had been no case of death. We must be attentive to the program of the new German coalition government, and its impact on the health system. It seems that its actions are concentrated in the pharmaceutical sector. The failure, for various reasons, of the COVAX platform for immunization of low- and middle-income countries is confirmed.

At the national level, the growth of COVID continues to figures that are already beginning to be worrying, despite the advantage over other European countries. The council of ministers approves the Mental Health Strategy, a plan that, unlike the one approved a few years ago on Primary Care, does have funding, despite having aroused reservations among experts. The council of ministers also approves the PERTE for health. As of December 13, the vaccines for children will be available.

Regarding companies, it should be noted that both Pfizer and Moderna are preparing to adapt their vaccines to the new COVID variant.

 

INTERNATIONAL

 

  • The WHO agrees on December 1, 2021 to begin negotiating an international agreement on how countries should prevent, prepare for and react to pandemics. The agreement is to hold a meeting before March 1, 2022 and discuss a draft before August 1, 2022 (British Medical Journal, Dec 2, 21)
  • A law to introduce dental care in Medicare is discussed in the American Congress (NEJM, 2 Dec 21)
  • An article is published that compares the evolution and behavior in 24 months of a large number of people from the Veterans Administration vaccinated with Moderna and Pfizer-BioNTech (NEJM, Dec 1 21)
  • The need for the health sector to contribute to decarbonization continues to be present (NEJM, Dec 2 21)
  • The WHO warns of a high risk due to the new “omicron” variant (FT Nov 29, 21)
  • WHO says there have been no deaths from the new “omicron” variant, despite its expansion (The Guardian, 4 Dec 21)
  • The “ómicron” variant, with a wide worldwide diffusion: apart from its origin in South Africa, and the expansion to 11 European countries, also present in Canada, Brazil, Australia and Saudi Arabia, among others (CNN Español, Dec 1 21)
  • Van der Leyden calls to discuss the mandatory nature of the vaccine (FT, Dec 1 21)
  • Analysts say that the economic impact of the “omicron” variant will not be important (FT, Nov 29, 21)
  • The program of the new German coalition government has an impact on the healthcare and pharmaceutical sector. Most important measures: price containment in medicines, push for healthcare digitization and use of medical data for research (Covington, Nov 29 21)
  • Biden rules out a new lockdown to tackle the new “omicron” variant (FT, Nov 29, 21)
  • The United Kingdom urgently calls a meeting of the G7 to discuss the problem of the new variant (La Razón, 28 Nov 21)
  • The new variant presents more than 50 mutations over the original from Wuhan (La Razón, Nov 29, 21)
  • COVAX has only distributed 26% of the promised covid vaccines for 2021. The most unanimous explanation is that rich countries have monopolized the market (El Español, Dec 4, 21)
  • The EMA would need three to four months to approve vaccines if they have to be modified by “omicron” (El Confidencial, Nov 30, 21)
  • Europe steps on the accelerator with the third doses in full uncertainty for the new variant (eldiario.es, Nov 29, 21)
  • The lack of vaccines, logistical limitations and the rejection of part of the population hinder immunization in Africa (El País, 28 Nov 21)
  • Germany imposes a de facto confinement to the unvaccinated: leisure and commerce will be banned (El País, 2 Dec 21)
  • Agreement between the Council and the European Parliament to strengthen the role of the ECDC (El Global, 30 Nov 21)

NATIONALS

 

  • COVID cases continue to rise, reaching an AI (cases per 100,000 in the last 14 days) of almost 250 (El Confidencial, Dec 3, 21)
  • Health advises limiting participants in social events during Christmas after the advance of COVID (La Razón 1 Dec 21)
  • The government does not have a “legal plan B” before the “omicron”, it trusts everything to vaccination and rejects restrictions that could affect the economy (La Razón, Dec 1 21)
  • The Government defends the need for an International Treaty on Pandemics, as stated by Minister Darias during the Extraordinary Assembly of the WHO in Geneva (ConSalud, 29 Nov 21)
  • The Council of Ministers approves the Mental Health Strategy 2022-2026, the last was of 2009. It is criticized by experts (Spanish Society of Psychiatry, Spanish Society of Dual Pathology) for its lack of ambition, although the effort of consensus. Among the criticisms is the lack of standards such as professional ratios, number of beds in children’s and adolescent hospitals, waiting lists, etc. It has financing of 100 million euros for the next three years, 30 million for 2022. Intervention in the workplace, the approach to suicide and the gender perspective, among the novelties of this Strategy (El Mundo, Dec 4, 21)
  • The council of ministers officially approves the PERTE for health. Investment of more than 1,400 million euros, between 2021 and 2023. These investment agendas are articulated through tenders, the creation of an investment, development and innovation (R + D + i) structure for advanced online therapies, launch of a public-private investment vehicle in advanced therapies (public-private commercial company) with the participation of companies with production capacity in Spain, elements of early coordination and identification of capacities and needs of the National Health System, public procurement innovative and pre-commercial, agreements with communities, private initiatives and co-programmed projects and public tenders (PlantaDoce, Nov 30 21)
  • The Interterritorial Council of December 2 addresses the Royal Decree of Specialties, so that it is approved before the end of 2021. It contemplates approving new specialties and reviewing access to specific training areas (ConSalud, Nov 30, 21)
  • Pfizer vaccines for children, available from December 13 (ConSalud, Dec 1 21)
  • AESEG presents a report “The sector of generic drugs in the economic and social reconstruction of Spain”, in which it advocates a differential price of generics in relation to brands (AESEG, Dec 1 21)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

 

  • Continuity of care, interoperability, innovation and the promotion of the SDGs (Sustainable Development Goals), among the objectives of the IDIS Foundation for 2022 (ConSalud, 2 Dec 21)
  • Teladoc Health grows 81% in the third quarter (PlantaDoce, Dec 1 21)
  • Pfizer and Moderna are preparing to adapt their vaccines to the new “omicron” variant (El Global, Nov 29, 29)
  • Merck’s COVID Treatment (Molnupiravir), Endorsed by FDA (NYT, Nov 30 21)
  • HM Hospitales will have a new space of 1,000 square meters in Valdedebas (PlantaDoce, Nov 30, 21)
  • HIPRA relies on its covid vaccine to grow 13% in 2021 (PlantaDoce, Dec 1 21)
  • The major private equity companies (CVC, Advent, Cinven, PAI, KKR,…) prepare offers for around 1,500 million for IVI (CincoDías, Nov 30, 21)

7 days in healthcare (15-21 November, 2021)

/in /by

 

ABSTRACT

From the international point of view, the plan of the American Democrats to negotiate the price of medicines and its possible impact on innovation continues to be discussed; Europe is once again the engine of the pandemic, with demonstrations in some European cities against confinements and COVID passport measures; and finally, the United States reach a peak in mortality from opioid as the covid pandemic continues.

At the national level, four elements of interest: 1. Spain exceeds 100 cases per 100,000 inhabitants, although the situation is worrying, nothing to do with that of other European countries; 2. The state-of-the-art health PERTE is presented, doubts regarding its reformist impact; 3. Publication of the draft law that aims to consolidate the universality and equity of our National Health System; 4. The waiting lists are published as of June 30, 2021.

In terms of company news, perhaps most relevant is that both Merck and Pfizer’s COVID therapies will be available in generics for low- and middle-income countries.

INTERNATIONAL

  • Request for action in Afghanistan, given the food emergency, by the director of the World Food Program. Disaster is the consequence of conflict, economic collapse and drought (The Lancet, Nov 20 21)
  • Intense debate in the USA about the consequences for pharmaceutical innovation of the regulatory framework on the price of drugs that the Biden Administration wants to approve (NEJM, Nov 18, 21)
  • Democrats in the USA have a plan to reduce the price of drugs, without harming innovation (The Economist, Nov 20 21)
  • A year after the decision of the British NHS to move towards zero carbon emissions by the health system, another 13 countries, including Spain, have joined this approach, which entails important changes, especially in supply chains (The Lancet, Nov 17 21)
  • Europe is once again the engine of the pandemic, with the extremely worrying situation in Austria, Germany, the Netherlands, Belgium, the United Kingdom, Ireland, Hungary, Romania and Russia, among others (Le Monde, 17 Nov 21)
  • Austria returns to lockdown (The Guardian, Nov 18 21)
  • Thousands of people protest in Vienna against confinement and mandatory vaccination (El País, 20 Nov 21)
  • Germany tightens restrictions on the unvaccinated and will force health workers and nursing home workers to be vaccinated (El País, 18 Nov 21)
  • Bavaria cancels Christmas markets, given the growth of the pandemic (The Guardian, 19 Nov 21)
  • The third dose can be extended to all adults, says British Health Minister Sajid Javid (The Guardian,
  • The majority of the European population, in favor of COVID passports (The Guardian, 19 Nov 21)
  • The use of masks reduces the incidence by 53%, according to an international study published in the British Medical Journal (The Guardian, 18 Nov 21)
  • In the USA, mortality from opioid overdose reaches record growth, while the pandemic continues (NYT, Nov 17, 21)
  • Fauci says the pandemic may be under control in 2022, with more third doses (The Guardian, Nov 17, 21)
  • Europe will prioritize the local manufacture of drugs to gain autonomy. This coming week the new EU pharmaceutical strategy will be approved (El Economista 21 Nov 21)

NATIONAL

  • Spain exceeds 100 cases per 100,000 inhabitants for the first time in two months (El País, 18 Nov 21). Comment: although the situation is worrying, it has nothing to do, however serious, with that of other parts of Europe. It seems that the high immunization, the fifth wave and the high percentage of vaccination are at the origin of this situation. However, we do not know if this differential is going to be maintained or we are heading towards a situation similar to that of most of the rest of Europe.
  • The autonomous communities denounce that they once again lack legal tools in the face of another wave of the pandemic (El Mundo, Nov 21, 21)
  • The state-of-the-art health PERTE is presented, which entails 1,489 million investment until 2023 (diariofarma, 15 Nov 21). Comment: there is no transformation in the sense of reforming the health system (which they consider good) and it is an investment aimed at the biotechnology industry. Mentions of primary care are imprecise. In summary: facing the transformation of the health system and to what extent European funds can help, including digitization, is an issue that remains to be seen
  • Published the Draft Law that modifies various regulations to consolidate equity, universality and cohesion of the National Health System, which seeks to prevent co-payments and promote direct management (Diario Médico, Nov 16 21)
  • Waiting lists published as of June 30, 2021: 121 days on average to undergo surgery and 75 days to visit a specialist. 661,162 people, waiting for an intervention. The lists are close to those in 2019 (La Vanguardia, Nov 26 21)
  • ASPE offers its collaboration to end the waiting lists (Medical Redaction, Nov 18 21)
  • Summer-22 is set as the limit to reform the Framework Statute in the summer of 2022, for which it is announced that there will be minor changes to adapt to the Basic Statute of Public Employees and the labour conditions of residents (Diario Médico, Nov 18, 21)
  • The Public Health Center will go to the Council of Ministers soon (Consalud, 19 Nov 21)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

  • Pfizer’s anticovid pill will be sold as a generic drug in 95 low- and middle-income countries, mainly in Africa and Asia, although the agreement excludes some countries hit hard by the pandemic. Previously, Merck had announced something similar (NYT, Nov 16 21)
  • European regulators, with serious doubts about Biogen’s Alzheimer’s drug (FT, Nov 17 21)
  • DKV remains in the MUFACE system (company declarations)
  • The EMA launches the emergency authorization process for the NOVAVAX vaccine, which would be the first vaccine with recombinant proteins developed in the European Union (Expansión, 18 Nov 21)
  • Quirónsalud launches two new phase I clinical trial units in Madrid and Barcelona, ​​following an agreement with Next Oncology (Diario Médico, 19 Nov 21)
  • Prim improves its profit by 90% in the first nine months of the year, to 12 million (PlantaDoce, Nov 15, 21)
  • Moderna appoints new general manager for Spain and Portugal, Juan Carlos Gil (PlantaDoce, Nov 16 21)
  • Miranza expands its presence in the Basque Country and opens a new center in Bilbao (PlantaDoce, 15 Nov 21)
  • The German biotechnology company CureVac will begin second-generation vaccine trials (ConSalud, 19 Nov 21)
  • Rovi expects to reach growth forecasts for 2023 this year (CincoDías, Nov 16, 21)
  • Pfizer, BioNTech and Moderna expect to bill 62,000 million euros in 2021 with their vaccines (CincoDías, 15 Nov 21)
  • The Spanish HIPRA vaccine will prove its effectiveness as a booster injection for Pfizer vaccinated (Expansión, 16 Nov 21)
  • USA will pay 4,650 million euros to Pfizer for 10 million anti-covid treatments (CincoDías, Nov 18, 21)
  • Almirall collapses on the stock market, after losing 40 million euros (Expansión, 15 Nov 21)

7 days in healthcare (1-7 november, 2021)

/in /by

 

 

ABSTRACT

From an international point of view, to highlight something we knew: that WHO, in its current configuration, is not prepared for global health challenges. However, this finding is important in the article in the British Medical Journal by Anthony Costello. Europe, once again in the center of expansion of the pandemic. The decision of the North American Democrats to reduce the price of medicines, via the negotiation in Medicare, is very far-reaching. This decision, if applied, will have major consequences for the entire pharmaceutical industry globally.

At the national level, to highlight the article in The Lancet, which says that Spain could have achieved group immunity. For the rest, the incidence of COVID continues to grow in our country, although it does not reach, by far, those of other European countries. Waiting lists are a big concern throughout Spain. Controversy over the new Equity, Universalization and Cohesion Law. Podemos wants to take advantage of it to repeal Law 15/1997, which allows the outsourcing of health services.

As a business activity, to highlight the two new antivirals against covid-19, one from Merck and the other from Pfizer. Merck has released the patent so that it can be used widely in developing countries. Novartis dissociates itself from Roche, selling it its 33% stake in the latter company.

INTERNATIONAL

  • The WHO, in its current configuration, is not ready for its purpose, but is limited by lack of funds and political interference, and this has been demonstrated in this pandemic that has produced more than 18 million deaths, writes the economist Anthony Costello in the British Medical Journal (BMJ, 3 Nov 21)
  • Europe once again at the center of the covid pandemic, says WHO, (The Guardian, 4 Nov 21)
  • The WHO warns of the increase in deaths from covid in 56 countries, and insists that vaccine manufacturers have not done their job well (ConSalud, 5 Nov 21)
  • Democrats in the United States reach an agreement to reduce the price of drugs, allowing the government to negotiate the price of Medicare drugs. The United States pays three times more for many drugs than Europe, according to a study by the Brookings Institution. Initially, the measure will be launched with the 12 most expensive drugs (FT, 2 Nov 21)
  • The fourth wave continues to beat the record of infections in Greece, with almost 7,000 daily (El Confidencial, 6 Nov 21)
  • Excess mortality grows in Russia, since the beginning of the pandemic (FT, 2 Nov 21)
  • The management of the pandemic leaves a trail of investigated political leaders: Brazil, France, Italy, Austria, India, … (El Debate, 2 Nov 21)
  • India’s successes against covid are analyzed: more than half of Indians have received at least one dose of the vaccine. 6 million are vaccinated every day (The Economist, 29 Oct 21)

NATIONAL

 

  • The Lancet suggests that Spain could have achieved group immunity. They are based on the high infections and the high percentage of vaccination (La Razón, 3 Nov 21)
  • The incidence of covid rises more than two points, to 53.7 cases per 100,000 inhabitants (El País, 5 Nov 21)
  • Madrid for the first time exceeds half a million patients to see the specialist. Experts warn that the pandemic has generated in Spain a dammed demand that will emerge in the coming semesters (El País, 5 Nov 21)
  • Spain, one of the five countries in which Covid-19 caused the greatest loss in life expectancy, according to a study published by the British Medical Journal (ABC, 3 Nov 21)
  • The Health Ministry sells a million vaccines to Australia, New Zealand and Paraguay, before they expire (El Español, 2 Nov 21)
  • The WHO requests to increase oral public coverage in Spain (Health Act. The proposal receives the support of the General Council of Dentists (Health Act, 5 Nov 21)
  • Podemos will not support the Darias Equity Law. The Ministry wants to promote a Law of Equity, Universality and Cohesion and Podemos does not support it by not repealing Law 15/1997, which allows the outsourcing of health services (ConSalud, 5 Nov 21)
  • The Health Ministry seeks location for its strategic reserve of covid material (El Periódico de España, 5 Nov 21)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

 

  • Merck drug effective to treat covid-19. The drug is an oral antiviral, called molnupiravir, and has already been approved by the British Agency. It has been launched by Merck and Ridbback Biotherapeutics, a Florida-based biotech. The drug is indicated for the unvaccinated and for those vaccinated who develop the disease. The treatment will be worth US $ 700 in developed countries. Merck will allow the development of generics in 105 countries (The Economist, 4 Nov 21)
  • Alphabet, Google’s parent company, launches an AI company, Isomorphic Labs, for the discovery of new drugs. It will work together with DeepMinds, Google’s AI company (FT, 4 Nov 21)
  • Pfizer increases the sales forecast of its covid vaccine in 2021 to 36,000 million US $ (FT, 2 Nov 21)
  • Biogroup, a bioanalysis group piloted by Stéphane Eimer and with a presence in Belgium, Luxembourg and the United Kingdom, enters the Iberian Peninsula with the purchase of Cerba Internacional and Analiza (both owned by Marcelo Weisz). ASISA will retain its 50% stake in Analiza (Les Echos, 4 Nov 21)
  • Novavax, a protein-based American covid-19 vaccine, receives its first approval in Indonesia. May promote immunization in developing countries. An application for authorization has also been sent to Canada, the United Kingdom and the European Union (FT, 1 Nov 21)
  • Pfizer announces an antiviral pill (Paxlovid) that prevents 89% of hospitalizations and deaths from covid (El País, 5 Nov 21)
  • The Valencian government will propose to the Data Protection Agency a sanction to Ribera for withholding data from the Torrevieja hospital (eldiario.es, Nov 4 21)
  • Centene closes the year of the coronavirus with losses in its health adventure in Spain (Nov 6, 21)
  • “Son Espases”: the macro-investigation on the concession to OHL of this hospital in the Balearic Islands, which links the Balearic Islands with the illegal financing of the PP (eldiario.es, Nov 5, 21)
  • Novartis sells its 33% stake to Roche for more than US $ 20 billion. A relationship of more than twenty years between the two companies is ended (PlantaDoce, Nov 4, 21)
  • MD Anderson launches a clinical trials unit (PlantaDoce, 3 Nov 21)
  • Eugin expands through Canada and acquires the fertility centers of Trio Fertility (PlantaDoce, 2 Nov 21)
  • Affidea, a European provider of diagnostic imaging, outpatient services and cancer care, expands in Spain and Northern Ireland with two new acquisitions (PlantaDoce, Nov 3, 21)
  • The biotechnology company of Spanish origin Aura Biosciences, jumps to the Nasdaq (PlantaDoce, 3 Nov 21)
  • Rovi doubles its profit in the first nine months of 2021, to 99 million (PlantaDoce, 3 Nov 21)